Section: N/A ReadChanges --- URL: https://www.washingtonpost.com/health/2021/07/05/aduhelm-new-alzheimers-drug-amyloid/ ISSN: 0190-8286 type: article-newspaper title: The controversial approval of an Alzheimer’s drug reignites the battle over the underlying cause of the disease source: www.washingtonpost.com abstract: The field of Alzheimer’s research has been dominated — and divided — by a hypothesis holding that toxic clumps in the brain are the main driver of the disease and that removing them will slow cognitive decline. language: en-US container-title: Washington Post --- is an article about Alzheimer's and the [amyloid hypothesis | amyloid hypothesis], a theory which seeks to explain the underlying cause of Alzheimer's [@Fx8A529A]. It was written in the context of the FDA's controversial [@FxB26E4E] decision to approve Aducanumab, a new, experimental drug for the treatment of Alzheimer's. It was written by Laurie McGinley and published by The Washington Post on July 5th, 2021. ## Text [a string of failures | a string of failures]. Years of testing drugs that target amyloid buildup have not yielded significant returns, and may be squeezing out other more promising approaches [@Ix4D05E7]. [Medicare’s finances | Medicare’s finances]. Aducanumab is an incredibly expensive treatment, and could undermine an already highly weakened Medicare system. ## Reference ReadChanges
